Core Viewpoint - Peijia Medical Limited reported a total revenue of RMB 353 million for the six months ending June 30, 2025, representing a 17.3% increase compared to the same period in 2024, with stable revenue contributions from TAVR and neurointerventional products [1] Financial Summary - The sales revenue from TAVR-related products increased by 24.0% to RMB 162 million, driven by an enhanced market share in China's TAVR market and a shift towards newly launched high-end products [2] - Neurointerventional products saw a 12.2% increase in sales revenue to RMB 192 million, supported by deeper market penetration of existing products and the successful launch of the YonFlow® stent [2] - The overall operating loss narrowed by 19.4% to RMB 68.32 million, with core business net loss significantly reduced by 52.4% to RMB 30.72 million [2] Cost Control and Efficiency - The TAVR business achieved commercial profitability for the first time, generating a profit of RMB 29.09 million, with sales and distribution expenses decreasing by 8.3% to RMB 100 million [4] - R&D expenses for the TAVR division decreased by 17.2% to RMB 54.2 million, primarily due to the completion of major clinical trials [4] - The management expenses slightly increased by 2.8% to RMB 50.98 million, mainly due to depreciation costs of a new headquarters [4] Innovation and Product Development - Three key in-development products are entering the registration application phase, including the TaurusTrio™ TAVR system, TaurusNXT® TAVR system, and GeminiOne® TEER system, with expected approvals between late 2025 and mid-2026 [5] - The DCwire® microguidewire and YonFlow® stent are highlighted as strong performers in the neurointerventional segment, with the former's sales revenue increasing nearly 140% [9] - The company is preparing for the market launch of the TaurusTrio™, which is expected to significantly enhance its competitive position in the AR valve market [5] Operational Efficiency - The neurointerventional division's profit increased by 42.4% to RMB 40.9 million, supported by effective cost control and operational efficiency measures [11] - The company has successfully integrated lean production and supply chain management to mitigate revenue pressures from centralized procurement [11] - The overall strategy emphasizes innovation-driven growth, operational efficiency, and maintaining market leadership in cardiovascular disease treatments [11]

智通财经APP讯，沛嘉医疗-B(09996)公布2025年上半年业绩，收入约3.53亿元，同比增长17.3%;毛利 2.48亿元，同比增长13.14%;研发开支约1.16亿元，同比增长15.1%。 公告称，收入可持续的收入增长主要归因于经导管瓣膜治疗业务及神经介入业务均实现强劲销售增长。 TAVR相关产品在报告期内的销售收入同比增加24.0%至1.62亿元，主要驱动力包括集团在中国经股 TAVR市场的进一步份额提升以及产品组合向新推出的高端产品倾斜。于报告期内，终端植入总量超过 2,050台，同比增长约18.8%，再次超越市场增长。 神经介入产品在报告期内的销售收入同比增加12.2%至1.92亿元。关键驱动因素包括：(i)现有产品(包括 DCwire®微导丝、Tethys AS®抽吸导管和 Fastunnel®输送型球囊扩张导管)市场渗透的深化;及(ii)新获批 的YonFlow®血流导向密网支架的成功上市。 报告期内，于2024年商业推出的DCwire®微导丝凭借卓越的产品性能显著扩大了市场份额，收入同比增 长近140%。2024年7月，公司正式提交其510(k)申请至美国FDA并获受理，预计将于2025年 ...

TAVR相关产品在报告期内的销售收入同比增加24.0%至人民币1.616亿元，主要驱动力包括集团在中国 经股TAVR市场的进一步份额提升以及产品组合向新推出的高端产品倾斜。于报告期内，终端植入总量 超过2,050台，同比增长约18.8%，再次超越市场增长。 格隆汇8月22日丨沛嘉医疗-B(09996.HK)发布公告，截至2025年6月30日止六个月，集团于报告期内的收 入为人民币3.534亿元，较2024年同期增加17.3%。收入构成保持稳定，其中45.7%来自TAVR相关产品销 售，54.3%来自神经介入产品销售(2024年上半年：分别为43.3%及56.7%)。可持续的收入增长主要归因 于经导管瓣膜治疗业务及神经介入业务均实现强劲销售增长。 神经介入产品在报告期内的销售收入同比增加12.2%至人民币1.918亿元。关键驱动因素包括：(i)现有产 品(包括DCwire®微导丝、Tethys AS®抽吸导管和Fastunnel®输送型球囊扩张导管)市场渗透的深化；及 (ii)新获批的YonFlow®血流导向密网支架的成功上市。 ...